Inspire Advisors LLC Invests $459,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Key Points

• Inspire Advisors LLC recently acquired a new stake in CRISPR Therapeutics AG, purchasing 13,475 shares valued at approximately $459,000.
• CRISPR Therapeutics' stock price dropped 7.4%, trading at $59.02, while its market capitalization stands at $5.10 billion.
• Analysts have varying outlooks on CRISPR Therapeutics, with a consensus rating of "Hold" and a median target price of $71.31.

Inspire Advisors LLC bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 13,475 shares of the company's stock, valued at approximately $459,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. SFE Investment Counsel raised its stake in shares of CRISPR Therapeutics by 5.8% in the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock worth $221,000 after buying an additional 355 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of CRISPR Therapeutics by 7.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock worth $215,000 after buying an additional 372 shares in the last quarter. Axxcess Wealth Management LLC raised its stake in shares of CRISPR Therapeutics by 4.0% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company's stock worth $351,000 after buying an additional 393 shares in the last quarter. GF Fund Management CO. LTD. raised its position in shares of CRISPR Therapeutics by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company's stock worth $74,000 after purchasing an additional 394 shares during the period. Finally, Capital Group Investment Management PTE. LTD. raised its position in shares of CRISPR Therapeutics by 2.1% during the fourth quarter. Capital Group Investment Management PTE. LTD. now owns 27,698 shares of the company's stock worth $1,090,000 after purchasing an additional 582 shares during the period. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Stock Down 0.3%

CRISPR Therapeutics stock traded down $0.20 during trading hours on Friday, hitting $56.07. The stock had a trading volume of 1,870,478 shares, compared to its average volume of 2,571,231. The company has a 50-day moving average of $48.88 and a two-hundred day moving average of $43.12. The company has a market cap of $4.84 billion, a PE ratio of -12.43 and a beta of 1.82. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. The business's quarterly revenue was up 71.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.43) earnings per share. As a group, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Wall Street Zen raised CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Barclays cut their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of "Hold" and a consensus price target of $71.31.

Insider Buying and Selling

In related news, insider Naimish Patel sold 3,932 shares of the stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the sale, the insider directly owned 6,068 shares in the company, valued at $218,083.92. This represents a 39.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Simeon George purchased 989,812 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The shares were acquired at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the transaction, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. The trade was a 133.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.